Uncategorized

3M Reports Second Quarter 2023 Results; Proactive Initiatives Drive Strong Quarterly Financial Results; Raises Full-Year Adjusted EPS Guidance

In the second quarter, the actions we took to strengthen our supply chain and restructure the company led to improved service for customers, reduced costs across 3M, and better than expected margins and cash flow,” said Mike Roman, 3M chairman and chief executive officer.

3M Reports Second Quarter 2023 Results; Proactive Initiatives Drive Strong Quarterly Financial Results; Raises Full-Year Adjusted EPS Guidance Read More »

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced the appointment of Nicole Sweeny as Chief Commercial Officer.

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer Read More »

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced the publication of its Phase 3 CARES 310 study results in The Lancet.

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet Read More »

Scroll to Top